Whitehawk Therapeutics, Inc.
Clinical trials sponsored by Whitehawk Therapeutics, Inc., explained in plain language.
A biopharmaceutical company developing therapies for rare diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
-
New drug HWK-016 takes aim at Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase study tests a new drug called HWK-016 in people with advanced ovarian or endometrial cancers that have not responded to other treatments. The drug is designed to deliver a toxic payload directly to cancer cells that carry a specific marker (MUC16). The main goals…
Phase 1 • Sponsor: Whitehawk Therapeutics, Inc. • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
New drug HWK-007 targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-stage study tests a new drug called HWK-007 in people with advanced solid tumors, including certain ovarian, endometrial, and lung cancers. The drug is designed to target a protein (PTK7) found on cancer cells and deliver a chemotherapy-like payload directly to them. T…
Phase 1 • Sponsor: Whitehawk Therapeutics, Inc. • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC